3P Biopharmaceuticals Enters U.S. Market

3P Biopharmaceuticals, a CDMO specializing in process development and cGMP manufacturing for biologics, opened its first commercial office in Boston, MA. This marks 3P’s first venture outside of Spain, and according to the company, strategically places it at the center of the world´s largest biopharma hub.

Dámaso Molero, CEO at 3P said, “The United States is considered one of the largest and most dynamic markets for biopharma worldwide. Establishing ourselves in Boston will allow 3P to access a broad and fast-growing market, enabling us to further drive our growth.”

In terms of global positioning, this endeavor will provide the Navarre-based CDMO with greater visibility and international recognition. This initial step into the American market will further enable the company to meet with new and existing clients and foster long-term partnerships with US-based companies.

Elena Erroba, chief commercial officer at 3P, said, “3P has always seen the undeniable business opportunity in the United States. This new commercial office will assist us in meeting the growing demands of our customers and consolidating our CDMO offering in North America.”

In a statement, 3P said that it is firmly committed to expanding its global presence in the biologics manufacturing sector as it embarks on this effort to broaden its global footprint.